Publications by authors named "Caro Verbrugghe"
Article Synopsis
- The study aimed to model how donor antibodies from convalescent plasma bind to the virus responsible for COVID-19, using an immunosorbent assay to measure the binding affinity of antibodies.
- Results showed that for IgG, 89% of plasma donations had complex binding affinities, with median values indicating significant differences in concentration compared to IgA.
- The model suggested that doubling the amount of convalescent plasma transfused could lead to effective binding to the virus if certain affinity and concentration thresholds are met, particularly in the early stages of infection.
Background: Convalescent plasma (CP) transfusion is an early option for treating infections with pandemic potential, often preceding vaccine or antiviral drug rollout. Heterogenous findings from randomized clinical trials on transfusion of COVID-19 CP (CCP) have been reported. However, meta-analysis suggests that transfusion of high titer CCP is associated with a mortality benefit for COVID-19 outpatients or inpatients treated within 5 days after symptom onset, indicating the importance of early administration.
View Article and Find Full Text PDFBackground: COVID-19 convalescent plasma (CCP) ideally contains high titers of (neutralizing) anti-SARS-CoV-2 antibodies. Several scalable immunoassays for CCP selection have been developed. We designed an enzyme-linked immunosorbent assay (ELISA) that measures neutralizing antibodies (of all isotypes) in plasma by determining the level of competition between CCP and a mouse neutralizing antibody for binding to the receptor binding domain (RBD) of SARS-CoV-2.
View Article and Find Full Text PDF